0RAE Stock Chart & Stats
€0.69
€0.00(0.00%)
At close: 4:00 PM EDT
€0.69
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.63 - €1.19
Previous CloseN/A
Volume4.00
Average Volume (3M)886.00
Market Cap
€53.20M
Enterprise Value€67.72M
Total Cash (Recent Filing)€4.72M
Total Debt (Recent Filing)€12.24M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding77,817,220
10 Day Avg. Volume869
30 Day Avg. Volume886
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)-13.62
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€4.05M
Bulls Say, Bears Say
Bulls Say
Proprietary Willaertia Magna PlatformOwning a distinct biological platform built around Willaertia magna is a durable competitive asset: it creates IP, differentiated product profiles and multiple application pathways (biocontrol, biofertilizer), supporting long-term licensing, partnerships and barrier to entry for commodity chemical competitors.
Multiple Structural Revenue ChannelsHaving product sales, licensing/partnerships, and R&D/service income provides resilience: it allows scaling via partners, milestone/royalty timing to smooth cash flow, and diverse go-to-market options as regulatory approvals and industrialization capacity progress.
Early Signs Of Improving Cash Flow And EquityModest improvements in free cash flow and a partial equity recovery suggest initial stabilization after deeper losses. If maintained, this indicates tighter cost control and a slowing burn rate, which can extend runway and improve ability to execute regulatory and commercial milestones.
Bears Say
Negative Equity And Rising LeverageSustained negative equity and material debt accumulation weaken financial flexibility and increase refinancing risk. This structural balance-sheet fragility makes funding product registrations, manufacturing scale-up and commercial launches more conditional on external capital or dilutive partnerships.
Revenue Collapse In 2025A complete collapse of reported revenue removes operating leverage and market validation, implying commercialization setbacks or lost market access. Over the medium term this raises execution risk: no recurring product sales to fund registrations, scale-up or partner negotiations.
Consistent Negative Operating And Free Cash FlowPersistent negative operating and free cash flow indicates ongoing cash burn requiring external financing. This constrains investment in manufacturing scale-up, regulatory dossiers and commercial expansion, increasing dilution risk or operational cutbacks if funding access tightens.
Amoeba SA News
0RAE FAQ
What was Amoeba SA’s price range in the past 12 months?
Amoeba SA lowest share price was €0.63 and its highest was €1.19 in the past 12 months.
What is Amoeba SA’s market cap?
Amoeba SA’s market cap is €53.20M.
When is Amoeba SA’s upcoming earnings report date?
Amoeba SA’s upcoming earnings report date is Sep 24, 2026 which is in 21 days.
How were Amoeba SA’s earnings last quarter?
Amoeba SA released its earnings results on Mar 26, 2026. The company reported -€0.066 earnings per share for the quarter.
Is Amoeba SA overvalued?
According to Wall Street analysts Amoeba SA’s price is currently Overvalued.
Does Amoeba SA pay dividends?
Amoeba SA does not currently pay dividends.
What is Amoeba SA’s EPS estimate?
Amoeba SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amoeba SA have?
Amoeba SA has 77,817,220 shares outstanding.
What happened to Amoeba SA’s price movement after its last earnings report?
Amoeba SA reported an EPS of -€0.066 in its last earnings report. Following the earnings report the stock price went down -8.588%.
Which hedge fund is a major shareholder of Amoeba SA?
Currently, no hedge funds are holding shares in GB:0RAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Amoeba SA
Amoéba S.A. focuses on the development and commercialization of anti-microbial and anti-fungal products. The company's primary innovation centers on harnessing the unique properties of the Willaertia magna C2c Maky amoeba, which it is applying across various fields. These applications are designed to mitigate biological risks in critical areas like water purification, the treatment of human injuries, and safeguarding agricultural crops. Established in 2010, Amoéba S.A. is based in Chassieu, France.